Chemotherapy as Second Hit in Desmoplakin Cardiomyopathy
Severe ventricular dysfunction during cancer therapy should prompt genetic evaluation, with cardiovascular magnetic resonance and genetic testing playing a key role in guiding diagnosis and risk stratification.
Authors
- Mariano Falconi (ORCID: https://orcid.org/0000-0001-9624-6424)
- Diego Pérez de Arenaza (ORCID: https://orcid.org/0000-0002-8582-5065)
- Giuseppe Andrea Ferro (ORCID: https://orcid.org/0000-0002-0622-4203)
- Rodolfo Pizarro (ORCID: https://orcid.org/0000-0002-3393-952X)
- Rocio Blanco
- Brogger Maria Noel
- Santiago del Castillo
- Bergier Mariano
Institutions
- Universidade da Coruña (ES)
- Johannes Gutenberg University Mainz (DE)
- Hospital Italiano de Buenos Aires (AR)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1016/j.jaccas.2026.107022
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00